GCS Inhibitor Synthesis via Segmented Carbamate Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic diseases and cancer, particularly those involving glucosylceramide synthase (GCS), face limitations in effectively inhibiting GCS activity to induce apoptosis in diseased cells and modulate sphingolipid patterns, especially in cases of multidrug resistance and excessive glycolipid synthesis.
Innovation Solution
A method for preparing specific compounds, such as (S)-quinuclidin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-ylcarbamate, through a series of reactions involving compounds of Formula II, III, V, VI, and VII, using reactants like imidazole, N,N'-carbonyldiimidazole, and quinuclidinol, to target GCS inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to inhibit GCS activity, then some therapeutic effect is achieved, but the inhibition effectiveness is insufficient to overcome multidrug resistance and induce apoptosis in diseased cells
Solution Approach 1:
The patent modifies the chemical structure of GCS inhibitors by changing parameters such as the introduction of fluorophenyl groups, thiazole rings, and carbamate linkages. These structural parameter changes enhance the inhibitory potency and selectivity of the compounds, enabling them to overcome multidrug resistance and effectively induce apoptosis in diseased cells while modulating sphingolipid patterns.
2Reliability
If existing GCS inhibitors are used, then some modulation of sphingolipid patterns occurs, but the ability to induce apoptosis and treat diseases is limited
Solution Approach 1:
The patent creates composite molecular structures by combining multiple functional groups (fluorophenyl, thiazole, carbamate, quinuclidine) into a single inhibitor molecule. This composite structure enables the compound to simultaneously achieve strong GCS inhibition, effective apoptosis induction, and modulation of sphingolipid patterns, thereby overcoming the limitations of existing inhibitors.
3Reliability
If new GCS inhibitors with enhanced activity are developed, then treatment effectiveness improves, but the complexity of synthesis and manufacturing increases
Solution Approach 1:
The patent employs a segmented synthetic approach where the complex GCS inhibitor is built step-by-step from simpler precursors. The synthesis is divided into discrete stages (forming intermediates with specific functional groups, then progressively assembling the final structure), which simplifies the manufacturing process while maintaining the complex bioactive structure needed for effective GCS inhibition and disease treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively synthesizes GCS inhibitors that can induce apoptosis in diseased cells, addressing multidrug resistance and modulating sphingolipid patterns, thereby providing a treatment option for various diseases, including metabolic disorders and cancers.
Implementation Method 1
The disclosure relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases
Implementation Method 2
A method for preparing specific compounds, such as (S)-quinuclidin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-ylcarbamate, through a series of reactions involving compounds of Formula II, III, V, VI, and VII
Data Source
AI summary
The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lyosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.